Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsM. Caplin, Zeng Zheng-Pei, Éric Baudin et al.|Annals of Oncology|2015Cited by 698
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Marcelo Garrido et al.|The Lancet Oncology|2023Cited by 614
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid ImagingAnders Sundin, Rudolf Arnold, Éric Baudin et al.|Neuroendocrinology|2017Cited by 495
Title Page / Table of ContentsKjel Öberg, Wolf O. Bechstein, Kjell Öberg et al.|Neuroendocrinology|2006Cited by 7